PharmAsia Summit 2013

PharmAsia Summit 2013

21-10-2013 - 23-10-2013 Grand Hyatt, Shanghai, China

The 2013 PharmAsia Summit will focus on new R&D and commercial models for a rapidly changing China biopharmaceutical market.

The 2013 PharmAsia Summit will focus on new R&D and commercial models for a rapidly changing China biopharmaceutical market. From the government's push for innovation to increased pricing pressure on off-patent medications to faster growth in China's second-tier markets, the biopharmaceutical market in China is undergoing fundamental changes that require new business models and new ways of thinking.

This year's summit features speakers from leading multinational and domestic pharmaceutical companies discussing new models to sustain growth via case studies, panels and keynote talks.

To kick-off the summit, we will release our second annual PharmAsia Summit Report, in collaboration with McKinsey, providing an in-depth analysis of trends critical to biopharmaceutical development and commercialization in the China market.

PharmAsia Summit 2013 keynotes include top pharma leaders from Roche, Sanofi and Cardinal Health

Featured participants include:

Ming Zhang, head of R&D China, Amgen

David Snow, president, China and Hong Kong, AstraZeneca

Jean-Christophe Pointeau, president, Bristol-Myers Squibb China

Eric Zwisler, president, Cardinal Health China

Liangshang Zhang, president of global R&D, Jiangsu Hengrui Medicine

Thad Huston, president, Xian Janssen Pharmaceutical, Johnson & Johnson

Franck Le Deu, leader of Greater China Healthcare Practice, McKinsey & Company

Sophie Kornowski-Bonnet, head of partnering, Roche Pharmaceuticals

Luke Miels, regional head, Asia Pacific, Roche Pharmaceuticals

Jean-Luc Lowinski, senior vice president Asia Region, Sanofi

Henry Sun, chief executive, Tasly Pharmaceuticals

Parexel

Parexel

Mitokyne

mitokyne-logo.jpg

Mitokyne is a Japan-based biotechnology company focused on mitochondria-related drug discovery and development services.

Back to top